Navigation Links
Anti-VEGF drugs for retinal diseases could have serious side effects, scientists caution
Date:11/3/2008

ia Sang of Ophthalmic Consultants of Boston points out that the use of anti-VEGF therapy in the treatment of patients with wet macular degeneration has revolutionized outcomes in this disease. However, in light of the work of Dr. D'Amore and others, in elucidating possible systemic and ocular side effects of these drugs, "caution must be exercised in identifying patients at increased risk of problems with long-=term VEGF blockade, and potential side effects must be detected early in the assessment of patients who will require repeated dosages of anti-VEGF agents."

The study is also relevant to the drug Avastin, which was initially approved for intravenous use as an anti-angiogenic agent in the treatment of cancer, but is also widely used intravitreally for the treatment of wet AMD because of its similar mode of action and much lower cost.

The next steps in D'Amore's research will include investigating the specific functions of VEGF in the eye.


'/>"/>

Contact: Patti Jacobs
pjacobs12@comcast.net
617-864-2712
Schepens Eye Research Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution
2. New review suggests caution on drugs to raise good cholesterol
3. Can cancer drugs combine forces?
4. Study provides hope that some transplant patients could live free of antirejection drugs
5. Study provides hope that some transplant patients could live free of anti-rejection drugs
6. RA Drugs Linked to Slight Skin Cancer Risk
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Rock N Roll: Sex, Drugs and an Early Exit
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... FRANCE (PRWEB) , ... September 02, 2015 , ... ... , PHYTOMER, the pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth ... This new cream combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil ...
(Date:9/2/2015)... ... 2015 , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, ... consecutive year. Less than 5 % of this year’s 5000 honorees share the “six-time” ... Pentec’s 3-year revenue growth rate of 65% sustained its most recent achievement. As an ...
(Date:9/2/2015)... ... September 02, 2015 , ... This Fall, as Ovarian ... Bright Pink, a national non-profit focused on the prevention and early detection of ... campaign to educate women to be breast and ovarian self-aware and celebrate positive, ...
(Date:9/1/2015)... Spring Lake, NJ (PRWEB) , ... September 01, ... ... physician, has a reputation for the telling the truth about medicine and health, ... has created a video blog, where he plans to regularly debunk certain misconceptions ...
(Date:9/1/2015)... ... 01, 2015 , ... September is National Prostate Cancer Awareness Month and Florida ... men each year in the United States. , Prostate cancer is to men what ... affecting 1 in 7 men. One new case occurs every 2.3 minutes and a ...
Breaking Medicine News(10 mins):Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3
... conducted survey has revealed that Irish hospitals are definitely ... ,The study carried out between February and ... Infection Society //looked into 75,000 cases has revealed that ... contracted during the stay at health centers across Ireland. ...
... fresh out of the college, are yet to land a permanent ... which sought responses from 500 newly qualified nurses and more than ... yet ended for a band 5 nursing job, which is the ... sentiment among nearly 86% of the nurses, who were not positive ...
... prefer not step in to fast-track a merger between Albury-Wodonga's ... with Tony Abbott and Goulburn Murray politicians yesterday. ,A ... governments has still not revealed a common plan towards working ... work as one. ,Mr Abbott states that the must ...
... According to researchers, stress among youth associated with parental ... ,The researchers at the John Moores University in Liverpool ... at times parents in recognizing the physical and emotional ... poor physical and mental health. ,According to ...
... Cancer drug Velcade has been banned in England because the ... Excellence (NICE) has refused// to fund treatment, according to last ... week that Velcade should not be offered on the NHS ... Presently a course of Velcade has been estimated to cost ...
... All batches of the paracetamol tablet Paratabs 500mg are being ... contamination which is most likely to be mould//. This applies ... could not have purchased the product without a prescription , ... their pharmacy and not to consume anymore Paratabs, while ...
Cached Medicine News:Health News:Stress brings about early onset of puberty 2
(Date:9/1/2015)... BRUSSELS , Sept. 1, 2015 ... (Euronext Brussels: UCB) today announced top-line results from ... Compared with Teriparatide in postmenopaUsal women with osteoporosis ... bisphosphonatE therapy). The study (NCT01796301) met the primary ... of romosozumab in the percent change of total ...
(Date:9/1/2015)... 2015  Dynatronics Corporation (NASDAQ: DYNT ) ... First Annual Ladenburg Thalmann Healthcare Conference at the ... H. Cullimore, Jr. , Chairman and President, is ... on Tuesday, September 29 at 10:30 a.m. EDT.  ... showcase leading-edge companies in the healthcare arena. Mr. ...
(Date:9/1/2015)... 1, 2015 Emerus Holdings, a national ... inpatient and diagnostic care in partnership with leading ... definitive agreement to receive a strategic investment from ... leading health care investment firm. Emerus ... acute episodic and ambulatory clinical services to communities ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... Speedus Corp. (Nasdaq: SPDE ) ("Company") today announced that on ... ended December 31, 2008, its Form 10-Q for the period ended ... June 30, 2009. As a result of these filings, Company ... with Nasdaq,s Marketplace Rule 5250(c)(1). Accordingly, this matter is now closed. ...
... SAN MATEO, Calif., Oct. 20 AlphaDetail, an innovator ... new features to its suite of tracking services: AlphaLink ... competitive landscape by integrating secondary research with tracking study ... is managing through vast amounts of data, gathered from ...
Cached Medicine Technology:Speedus Announces Compliance with Nasdaq Marketplace Rules 5250(c)(1) and 4350(b)(1)(B), and Receipt of Noncompliance Notification Related to Nasdaq Marketplace Rule 5550 2AlphaDetail Tracking Study Enhancements: The Advantage of Integration and Speed 2
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: